Comparison
Exenatide vs. Hexarelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
141758-74-9
140703-51-1
Molecular weight
4186.6 g/mol
887.05 g/mol
Half-life
2.4 h
0.9 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSHis-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
4
3
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
2
1